Obagi Medical and DermFx Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

Core Insights - DermFx has been selected as a key partner for Obagi Medical's ALOHA Program, focusing on real-world data generation to validate the clinical safety and efficacy of Obagi's Hyaluronic Acid products in everyday practice [1][2] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, known for addressing various skin concerns and recognized as the fastest-growing professional skincare brand in the U.S. in 2024 [5] - DermFx is a top-ranked medical spa in Southern California, specializing in advanced aesthetic treatments and has served tens of thousands of patients over 20+ years, emphasizing exceptional patient care and personalized protocols [6][7] - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [8] Partnership Details - The partnership aims to provide DermFx with access to cutting-edge protocols and real-world insights, enhancing patient outcomes and allowing independent med spas to compete effectively [2][3] - The ALOHA Real-World Program will offer DermFx providers hands-on experience with Obagi saypha MagIQ™, utilizing proprietary technology for improved aesthetic results [3] Program Objectives - The ALOHA Program is designed to drive patient satisfaction and strengthen relationships between patients and DermFx providers through structured evaluations and standardized data capture [2] - Initial findings from the program will be presented at internal team meetings and regional events to highlight the benefits of the new protocols and products [2]